ScreenerHero
LKFTLAKEFRONT BIOTHERAPEUTICS
AMS · NL · Healthcare · Biotechnology · lakefrontbio.com
24.92EUR+2.38%Mkt Cap: 1.77B $P/E: 2.76

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap1.77B $
Enterprise Value-690.37M $
Revenue (TTM)1.08B $
Gross Profit1.18B $
Net Income (TTM)348.79M $
Revenue/Share16.34 USD
Last Price24.92 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees452
CountryNL
SectorHealthcare
IndustryBiotechnology
ISINBE0003818359
Valuation
P/E (Trailing)2.76
P/E (Forward)-6.22
PEG—
EV/EBITDA-1.12
EV/Revenue-0.64
P/S1.61
P/B0.49
EPS (TTM)9.02
EPS (Forward)-3.91
52W Range
22.3225% of range32.74
52W High32.74 EUR
52W Low22.32 EUR
Profitability
Gross Margin97.33%
Oper. Margin-359.30%
EBITDA Margin57.43%
Profit Margin28.85%
ROE9.92%
ROA9.42%
Growth
Revenue Growth-81.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-279.84M $
CapEx (TTM)15.06M $
FCF Margin13.95%
FCF Yield8.47%
Net Debt-2.43B $
Net Debt/EBITDA-3.93
Balance Sheet
Debt/Equity0.00
Current Ratio32.84
Quick Ratio32.65
Book Value/Sh49.37 EUR
Cash/Share34.11 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.4 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.27 EUR
Upside (mean)+21.5%
Target Range19.00 EUR – 44.80 EUR
€19.00+21.5% to mean€44.80
# Analysts8
Ownership
Shares Out.65.48M
Float24.30M
Insiders25.36%
Institutions43.29%
Technical
SMA 5025.02 (-0.4%)
SMA 20026.22 (-5.0%)
Beta0.11
S&P 52W Chg18.16%
Avg Vol (30d)91.15K
Avg Vol (10d)124.80K
Technical Indicators
RSI (14)49.4
MACD-0.1914
MACD Signal-0.3545
MACD Hist.+0.1631
BB Upper25.50 EUR
BB Middle24.03 EUR
BB Lower22.56 EUR
BB Width12.25%
ATR (14)0.8436 EUR
Vol Ratio (20d)1.03x